Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Share-based Compensation (2023 - 2025)

Immunome (IMNM) has disclosed Share-based Compensation for 3 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 44.3% year-over-year to $7.9 million, compared with a TTM value of $25.7 million through Dec 2025, up 63.13%, and an annual FY2025 reading of $25.7 million, up 63.13% over the prior year.
  • Share-based Compensation was $7.9 million for Q4 2025 at Immunome, up from $6.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.9 million in Q4 2025 and bottomed at $1.0 million in Q2 2023.
  • Average Share-based Compensation over 3 years is $4.0 million, with a median of $4.1 million recorded in 2024.
  • The sharpest move saw Share-based Compensation surged 351.71% in 2024, then skyrocketed 37.92% in 2025.
  • Year by year, Share-based Compensation stood at $2.9 million in 2023, then surged by 89.73% to $5.5 million in 2024, then surged by 44.3% to $7.9 million in 2025.
  • Business Quant data shows Share-based Compensation for IMNM at $7.9 million in Q4 2025, $6.7 million in Q3 2025, and $5.3 million in Q2 2025.